{"id":854738,"date":"2025-06-10T22:12:51","date_gmt":"2025-06-11T03:12:51","guid":{"rendered":"https:\/\/newsycanuse.com\/index.php\/2025\/06\/10\/novel-jak-inhibitor-improves-qol-in-chronic-hand-eczema\/"},"modified":"2025-06-10T22:12:51","modified_gmt":"2025-06-11T03:12:51","slug":"novel-jak-inhibitor-improves-qol-in-chronic-hand-eczema","status":"publish","type":"post","link":"https:\/\/newsycanuse.com\/index.php\/2025\/06\/10\/novel-jak-inhibitor-improves-qol-in-chronic-hand-eczema\/","title":{"rendered":"Novel JAK Inhibitor Improves QOL in Chronic Hand Eczema"},"content":{"rendered":"<div check-ads-type=\"true\">\n<h2><strong>TOPLINE:<\/strong><\/h2>\n<p>Treatment with delgocitinib cream, a topical pan-Janus kinase inhibitor, resulted in a significant improvement in health-related quality of life in patients with moderate to severe chronic hand eczema (CHE), with those receiving delgocitinib cream 20 mg\/g showed greater improvements in quality-of-life measures than those receiving vehicle cream over 16 weeks.<\/p>\n<h2><strong>METHODOLOGY:<\/strong><\/h2>\n<ul>\n<li>This phase 2b, randomised, double-blind, five-arm, cream vehicle-controlled clinical trial evaluated the efficacy and safety of topical delgocitinib cream in 305 participants from November 2018 through April 2020.<\/li>\n<li>Participants with mild to severe CHE and an inadequate response to topical corticosteroids, or for whom topical corticosteroids were medically inadvisable, received delgocitinib cream or vehicle cream for 16 weeks.<\/li>\n<li>The primary endpoint was the Investigator&#8217;s Global Assessment for CHE treatment success. This study evaluated patient-reported outcomes (PROs) in patients with mild and moderate to severe CHE at screening and the impact of delgocitinib on PROs in patients with moderate to severe CHE.<\/li>\n<li>PROs were collected using the Dermatology Life Quality Index (DLQI), EuroQOL-5 Dimensions-5 Levels (EQ-5D-5L), and Hand Eczema Impact Scale (HEIS) at screening, baseline, and weeks 1, 4, 8, 12, and 16.<\/li>\n<\/ul>\n<h2><strong>TAKEAWAY:<\/strong><\/h2>\n<ul>\n<li>Mean DLQI, EQ-5D-5L, and HEIS scores were 8.1, 0.788, and 1.7, respectively, for participants with mild CHE (n<em>\u00a0<\/em>= 93) and 12.1, 0.689, and 2.3, respectively, for those with moderate to severe CHE (n = 202).<\/li>\n<li>Participants with moderate to severe CHE who received delgocitinib cream 20 mg\/g (n = 41) showed a greater improvement in DLQI scores than those who received vehicle cream (n = 38) (least squares mean difference [LSMD], \u22122.5; <em>P<\/em> < .05).<\/li>\n<li>A superior improvement in EQ-5D-5L index scores was observed with delgocitinib vs vehicle cream (LSMD, 0.132; <em>P<\/em> < .01).<\/li>\n<li>Similarly, HEIS total scores were higher with delgocitinib cream than with vehicle cream (LSMD, \u22120.7; <em>P<\/em> < .01).<\/li>\n<\/ul>\n<h2><strong>IN PRACTICE:<\/strong><\/h2>\n<p>&#8220;The findings of the present study demonstrate that CHE is associated with a high patient burden, particularly for those patients with moderate to severe CHE. Furthermore, the results suggest that delgocitinib cream can potentially provide a new treatment option in a disease where there is a high unmet patient need,&#8221; the authors wrote.<\/p>\n<h2><strong>SOURCE:<\/strong><\/h2>\n<p>This study was led by Timo Buhl, Department of Dermatology, Venereology and Allergology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany. It was <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01384-4\">published online<\/a> on April 05, 2025, in <em>Dermatology and Therapy<\/em>.<\/p>\n<h2><strong>LIMITATIONS:<\/strong><\/h2>\n<p>Participants included at screening may not be representative of patients under standard care in clinical practice. The analysis of delgocitinib cream included only a limited number of participants with moderate to severe CHE. Additionally, as this was a multinational study, cultural and country-specific differences may have affected patient responses, with samples being too small to investigate potential differences between countries.<\/p>\n<h2><strong>DISCLOSURES:<\/strong><\/h2>\n<p>This trial was sponsored by LEO Pharma A\/S. Four authors reported being employees of LEO Pharma A\/S. Several authors reported being speaker or advisor and having other ties with various sources.\u00a0<\/p>\n<p><em>This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<p> Bong Latson <br \/><a href=\"https:\/\/www.medscape.com\/viewarticle\/novel-jak-inhibitor-improves-qol-chronic-hand-eczema-2025a10008d6\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TOPLINE: Treatment with delgocitinib cream, a topical pan-Janus kinase inhibitor, resulted in a significant improvement in health-related quality of life in patients with moderate to severe chronic hand eczema (CHE), with those receiving delgocitinib cream 20 mg\/g showed greater improvements in quality-of-life measures than those receiving vehicle cream over 16 weeks. METHODOLOGY: This phase 2b<\/p>\n","protected":false},"author":1,"featured_media":854739,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40170,28077],"tags":[144521,12753],"class_list":{"0":"post-854738","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-inhibitor","8":"category-novel","9":"tag-inhibitor","10":"tag-novel"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/854738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/comments?post=854738"}],"version-history":[{"count":0,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/854738\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media\/854739"}],"wp:attachment":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media?parent=854738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/categories?post=854738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/tags?post=854738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}